BiotechTube

Padsevonil

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Elderly Study Participants

Conditions

Elderly Study Participants, Adult Study Participants

Trial Timeline

Jul 9, 2019 → Oct 3, 2019

NCT ID
NCT04013191

About Padsevonil

Padsevonil is a phase 1 stage product being developed by UCB for Elderly Study Participants. The current trial status is completed. This product is registered under clinical trial identifier NCT04013191. Target conditions include Elderly Study Participants, Adult Study Participants.

What happened to similar drugs?

1 of 2 similar drugs in Elderly Study Participants were approved

Approved (1) Terminated (0) Active (1)
✅DonepezilEisaiApproved
🔄EsmirtazapineMerckPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04136444Phase 1Terminated
NCT04075409Phase 1Completed
NCT04013191Phase 1Completed
NCT03370120Phase 2Terminated
NCT03373383Phase 2Completed

Competing Products

15 competing products in Elderly Study Participants

See all competitors
ProductCompanyStageHype Score
YM150 + PlaceboAstellas PharmaPhase 1
29
ASP3325 + PlaceboAstellas PharmaPhase 1
29
E2022 Tape FormulationEisaiPhase 1
29
DonepezilEisaiApproved
43
AZD3293 + PlaceboAstraZenecaPhase 1
29
TC-5214 + PlaceboAstraZenecaPhase 1
29
AZD3293 + PlaceboAstraZenecaPhase 1
29
EsmirtazapineMerckPhase 3
40
Pertuzumab + trastuzumab + Pertuzumab + trastuzumab + metronomic chemotherapyRochePhase 2
35
PF-06648671 + Midazolam + PlaceboPfizerPhase 1
29
PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + PlaceboPfizerPhase 1
21
Vitamin D + Sham Exercise + Vitamin D + ExercisePfizerPhase 1
21
HSK3486 + HSK3486 + HSK3486 + HSK3486Haisco Pharmaceutical GroupPhase 1
29
TD-1439 + PlaceboTheravance BiopharmaPhase 1
23
TD-0714 + PlaceboTheravance BiopharmaPhase 1
23